

PTO Form PTO/SB/08: Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

1 of 2

Complete if Known

Application Number	09/724,778
Filing Date	November 28, 2000
First Named Inventor	Jeffrey Finer
Art Unit	1624
Examiner Name	Bruck Kifle
Attorney Docket Number	09367.0018-06000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS <i>class/subclass</i>					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
TNT	✓	US-2004-0254203-A1	12-16-2004	Finer et al.	
	✓	US-2005-0187232-A1	08-25-2005	Finer et al.	
	✓	US-7,009,049-B2	03/07/2006	Bergnes et al.	
TNT	✓	US-2006/0041130-A1	02/23/2006	Bergnes et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
TNT		WO/01/74344 A2	10-11-2001	Curis, Inc.		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation ⁶
TNT	✓01	Notice of Allowance mailed October 17, 2002, for U.S. Patent Application No. 09/699,047, filed October 24, 2000.		
	✓02	Notice of Allowance mailed February 4, 2003, for U.S. Application No. 09/724,644, filed November 28, 2000.		
	✓03	Notice of Allowance mailed February 6, 2003, for U.S. Application No. 09/724,713, filed November 28, 2000.		
	✓04	Notice of Allowance mailed October 14, 2004, for U.S. Application No. 09/724,897, filed November 28, 2000.		
	✓05	Notice of Allowance mailed October 24, 2005, for U.S. Application No. 09/724,897, filed November 28, 2000.		
TNT	✓06	Notice of Allowance mailed March 22, 2006, for U.S. Application No. 09/724,897, filed November 28, 2000.		

Examiner Signature	<i>[Signature]</i>	Date Considered	12/7/06
--------------------	--------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	PTO/SB/08: Substitute for form 1449A/PTO		Complete if Known	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/724,778
			Filing Date	November 28, 2000
			First Named Inventor	Jeffrey Finer
			Art Unit	1624
			Examiner Name	Bruck Kifle
2 of 2		Attorney Docket Number	09367.0018-06000	

NON PATENT LITERATURE DOCUMENTS		
TMC ✓	07	Notice of Allowance mailed April 28, 2004, for U.S. Application No. 09/724,941, filed November 28, 2000.
✓	08	Office Action mailed December 20, 2005, for U.S. Application No. 10/893,929, filed July 20, 2004..
✓	09	Notice of Allowance mailed December 11, 2003, for U.S. Application No. 10/300,967, filed November 20, 2002.
✓	10	Office Action mailed April 4, 2005, for U.S. Application No. 10/366,828, filed February 14, 2003
✓	11	Notice of Allowance mailed July 26, 2005, for U.S. Application No. 10/366,828, filed February 14, 2003
✓	12	Office Action mailed April 19, 2006, for U.S. Application No. 11/254,211, filed October 20, 2005.
✓	13	Office Action mailed April 12, 2006, for U.S. Application No. 10/312,323, filed August 15, 2003.
✓	14	"Cytokinetics Announces Clinical and Non-Clinical Data on Ispinesib to be Presented at the 2005 AACR-NCI-EORTC International Meeting-Data from Two Phase Ib Combination Trials to be Presented," <i>Press Release</i> , Cytokinetics, Inc., 3 pages, (11/10/2005).
✓	15	"Cytokinetics Announces Clinical and Non-Clinical Results on Ispinesib at the 2005 AACR-NCI-EORTC International Meeting-Data from Two Phase Ib Combination Trials Presented," <i>Press Release</i> , Cytokinetics, Inc., 4 pages, (11/17/2005).
✓	16	"Cytokinetics Announces Interim Phase II Breast Cancer data for Ispinesib to be presented at San Antonio Breast Cancer Symposium," <i>Press Release</i> , Cytokinetics, Inc., 3 pages, (12/1/2005).
✓	17	"Cytokinetics Announces Presentation of Ispinesib data at San Antonio Breast Cancer Symposium- Anti-cancer Activity Supportive of Continuation of Phase II Clinical Trial," <i>Press Release</i> , Cytokinetics, Inc., 3 pages, (12/8/2005).
✓	18	"Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non-Small Cell Lung Cancer- Drug Candidate Does No Demonstrate Sufficient Anti-Tumor Activity to Proceed to Sage 2 in the Phase II Clinical Trial Drug Candidate Demonstrates Disease Stabilization in 50% of Patients," <i>Press Release</i> , Cytokinetics, Inc., 5 pages, (03/30/2006).
✓	19	"Cytokinetics and GlaxoSmithKline Announce Seven Presentations At The 2002 Annual Meeting Of The American Association for Cancer Research- Broad Alliance to Generate First IND in 2002," <i>Press Release</i> , Cytokinetics, Inc., 4 pages, (04/08/2002).
✓	20	"Cytokinetics Announces the Initiation of a Broad Phase II Clinical Trials Program in Oncology for SB-715992- Milestone Payment Triggered under Collaboration with GlaxoSmithKline," <i>Press Release</i> , Cytokinetics, Inc., 3 pages, (01/14/2004).
✓	21	"Cytokinetics Publication in Cancer Research Demonstrates Antitumor Activity of a Kinesin Spindle Protein (KSP) Inhibitor in a Preclinical Model- Preclinical Proof of Concept Emerges from Company's Research Efforts," <i>Press Release</i> , Cytokinetics, Inc., 3 pages, (05/03/2004).
✓	22	"Cytokinetics Announces Phase I Results for SB-715992 to be Presented at the 2004 Annual Meeting Of The American Society of Clinical Oncology," <i>Press Release</i> , Cytokinetics, Inc., 2 pages, (06/02/2004).
✓	23	"Cytokinetics Announces Phase I Results for the SB-715992 presented at the 2004 Annual Meeting Of The American Society of Clinical Oncology- Safety and Tolerability Profile of the SB-715992 Supports Initiation of Broad Phase II Program," <i>Press Release</i> , Cytokinetics, Inc., 3 pages, (06/07/2004).
TMC ✓	24	"Cytokinetics Announces the Initiation of an Additional Phase II Clinical Trial for Lead Cancer Drug Candidate- Company Provides Update on Clinical Trials Program for SB-715992 and SB-743921," <i>Press Release</i> , Cytokinetics, Inc., 4 pages, (12/16/2004).

Examiner Signature		Date Considered	12/7/06
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

EV747261705US	August 24, 2006
USPS Express Mail Label Number	Date of Deposit

I hereby certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By: _____

Neely J. Kifle